Resistance to Integrase Inhibitors

Resistance to Integrase Inhibitors

Integrase (IN) is a clinically validated target for the treatment of human immunodeficiency virus infections and raltegravir exhibits remarkable clinical activity. The next most advanced IN inhibitor is elvitegravir. However, mutant viruses lead to treatment failure and mutations within the IN codin...

Full description

Bibliographic Details
Main Authors:	Mathieu Métifiot, Christophe Marchand, Kasthuraiah Maddali, Yves Pommier
Format:	Article
Language:	English
Published:	MDPI AG 2010-06-01
Series:	Viruses
Subjects:	AIDS HIV-1 integrase Raltegravir Elvitegravir GSK-1349572 GSK-1265744 interfacial inhibitors resistance
Online Access:	http://www.mdpi.com/1999-4915/2/7/1347/

Similar Items

HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?
by: Vogel Martin, et al.
Published: (2009-11-01)

Multiple choices for HIV therapy with integrase strand transfer inhibitors
by: Raffi Francois, et al.
Published: (2012-12-01)

Short Communication: Integrase Strand Transfer Inhibitors Drug Resistance Mutations in Puerto Rico HIV-Positive Individuals
by: Pablo López, et al.
Published: (2021-03-01)

Inhibition of HTLV-1 Infection by HIV-1 First- and Second-Generation Integrase Strand Transfer Inhibitors
by: Michał S. Barski, et al.
Published: (2019-08-01)

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
by: Nicola Gianotti, et al.
Published: (2017-11-01)

Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence
by: Thibault Mesplède, et al.
Published: (2015-07-01)

HIV INTEGRASE INHIBITORS: THE BASIS OF EFFECTIVE AND SAFE ANTIRETROVIRAL THERAPY
by: V. I. SHAKHGILDYAN
Published: (2017-05-01)

Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens
by: Aleksey Viktorovich Kravchenko, et al.
Published: (2010-11-01)

Integrase inhibitors versus efavirenz combination antiretroviral therapies for TB/HIV coinfection: a meta-analysis of randomized controlled trials
by: Yuanlu Shu, et al.
Published: (2021-05-01)

Resistance to inhibitors of the human immunodeficiency virus type 1 integration
by: Daria J Hazuda

G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to Raltegravir whereas Y143C does not
by: Damond Florence, et al.
Published: (2011-08-01)

HIV Integrase Inhibitor Pharmacogenetics and Clinical Outcomes: An Exploratory Association Study
by: Murrell, Derek E
Published: (2018)

HIV-1 Integrase-Targeted Short Peptides Derived from a Viral Protein R Sequence
by: Xue Zhi Zhao, et al.
Published: (2018-07-01)

HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland
by: Parczewski Miłosz, et al.
Published: (2012-12-01)

Raltegravir-Induced Adaptations of the HIV-1 Integrase: Analysis of Structure, Variability, and Mutation Co-occurrence
by: Lucas de Almeida Machado, et al.
Published: (2019-09-01)

Modern antiretroviral regimens
by: A. V. Kravchenko
Published: (2016-12-01)

HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study
by: Aurelio Orta-Resendiz, et al.
Published: (2020-02-01)

Novel therapeutic strategies targeting HIV integrase
by: Quashie Peter K, et al.
Published: (2012-04-01)

Quantitative prediction of integrase inhibitor resistance from genotype through consensus linear regression modeling
by: Van der Borght Koen, et al.
Published: (2013-01-01)

Chemistry and Structure-Activity Relationship of the Styrylquinoline-Type HIV Integrase Inhibitors
by: Didier Desmaële, et al.
Published: (2010-04-01)

Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors
by: Rossana Scutari, et al.
Published: (2020-03-01)

HIV drug resistance against strand transfer integrase inhibitors
by: Kaitlin Anstett, et al.
Published: (2017-06-01)

HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens
by: Pablo Ferrer, et al.
Published: (2020-09-01)

Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro
by: Selvi Kunnimalaiyaan, et al.
Published: (2018-05-01)

HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors
by: Pratibha C Koneru, et al.
Published: (2019-05-01)

Genetic Analysis of HIV-1 Integrase Sequences from Treatment Naive Individuals in Northeastern South Africa
by: Julius Nwobegahay, et al.
Published: (2013-03-01)

GSK-3 inhibitors: preclinical and clinical focus on CNS
by: Hagit eEldar-Finkelman, et al.
Published: (2011-10-01)

Generation of soluble, catalytically active covalent HIV-1 subtype C integrase-DNA complexes to identify novel strand transfer inhibitors
by: Beyleveld, Grant James
Published: (2014)

The study of susceptibility and resistance of HIV integrases to integrase strand transfer inhibitors and the development of novel single domain antibody targeting HIV integrase
by: Ni, Xiaoju
Published: (2011)

Are new antiretroviral treatments increasing the risks of clinical obesity?
by: Andrew Hill, et al.
Published: (2019-01-01)

Raltegravir: molecular basis of its mechanism of action
by: Mouscadet Jean-François, et al.
Published: (2009-11-01)

Analysis of Potential GSK-3 Inhibitors via in Vitro and ex Vivo Assays
by: Behme, Caitlin N.
Published: (2020)

Study on suitable analysis method for HIV-1 non-catalytic integrase inhibitor
by: Ki Hoon Park, et al.
Published: (2021-01-01)

The HIV-1 integrase-LEDGF allosteric inhibitor MUT-A: resistance profile, impairment of virus maturation and infectivity but without influence on RNA packaging or virus immunoreactivity
by: Céline Amadori, et al.
Published: (2017-11-01)

Microwave Assisted Organic Synthesis (MAOS) of Small Molecules as Potential HIV-1 Integrase Inhibitors
by: Alba Chimirri, et al.
Published: (2011-08-01)

GSK-3 inhibitors in glioblastoma therapy: mechanisms of action
by: Handley, Meghan Victoria
Published: (2016)

Integrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo Acids
by: Vasu Nair, et al.
Published: (2015-07-01)

The inhibitors of cyclin-dependent kinases and GSK-3β enhance osteoclastogenesis
by: Yosuke Akiba, et al.
Published: (2016-03-01)

Inhibition of HIV-1 integrase by [alpha]-luffin and RNA interference.
Published: (2005)

Integrase-RNA interactions underscore the critical role of integrase in HIV-1 virion morphogenesis
by: Jennifer L Elliott, et al.
Published: (2020-09-01)